~~<i id='49F93D9F9D'><strike id='49F93D9F9D'><tt id='49F93D9F9D'><pre id='49F93D9F9D'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：focus 2025-09-29 09:38:43 Page View：2377

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What don’t we know about an Alzheimer’s drug side effect?
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

BIO selects John Crowley as new CEO

JohnCrowleypicturedwithhisdaughterMegan.CrowleyfamilyWASHINGTON— TheBiotechnologyInnovationOrganizat

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Industry veterans launch new biotech VC with $310M

AdobeThreebiotechVCveterans,includingoneoftheco-foundersofradiopharmasuccessstoryRayzeBio,arelaunchi